June brought a broad range of regulatory developments across the UK, Europe and the United States, highlighting continued momentum in oncology, neurology, obesity, autoimmune diseases and rare conditions.

Roche’s Enspryng (satralizumab) received FDA Priority Review as a potential at-home treatment for moderate-to-severe thyroid eye disease, while Gilead’s Trodelvy became the first antibody-drug conjugate approved in Europe for first-line metastatic triple-negative breast cancer. Sanofi also secured European Commission approval for Cenrifki (tolebrutinib), the first disease-targeting therapy for adults with non-relapsing secondary progressive multiple sclerosis.

Regeneron’s cemdisiran was accepted for regulatory review by both the FDA and EMA for generalised myasthenia gravis, while Sanofi’s Sarclisa became the UK’s first anti-cancer treatment approved for administration via an on-body injector, offering greater convenience for patients with multiple myeloma.

The FDA also accepted Gilead’s application for a once-weekly oral formulation of Yeztugo (lenacapavir) for HIV prevention, while Alexion’s Ultomiris received Priority Review for immunoglobulin A nephropathy. In the UK, Novo Nordisk’s oral Wegovy became the first daily GLP-1 tablet approved for weight management, providing an alternative to injectable therapies.

Further regulatory progress included FDA Priority Review for Roche’s Tecentriq in stage 3 colon cancer, FDA Breakthrough Therapy Designation for Biogen’s investigational spinal muscular atrophy treatment salanersen, and an expanded FDA approval for Eli Lilly’s Ebglyss, allowing eligible patients with atopic dermatitis to receive maintenance treatment every eight weeks.

Alongside product developments, the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) reviewed several newly identified safety signals involving oncology medicines, immune checkpoint inhibitors, antibiotics, lithium, valproate and other established therapies, reflecting the continued importance of pharmacovigilance in protecting patient safety.

Advances in research and innovative therapies

Research activity continued to deliver encouraging results across oncology, neuroscience, rare diseases and clinical development, alongside growing discussion around patient-centred clinical trial design and evidence generation.

Takeda reported positive phase 3 data for oveporexton in narcolepsy type 1, demonstrating improvements in daytime functioning, cognition and sleep quality by addressing the underlying orexin deficiency. Johnson & Johnson also announced positive phase 3 results for Erleada in high-risk prostate cancer, while Bristol Myers Squibb and SystImmune reported significant survival benefits for their investigational bispecific antibody-drug conjugate across multiple difficult-to-treat cancers.

Oxford BioTherapeutics advanced several oncology programmes through its long-standing collaboration with Boehringer Ingelheim, Pfizer announced further findings from its investigational lung cancer therapy sigvotatug vedotin, and J-Pharma progressed nanvuranlat directly into global phase 3 development following alignment with the FDA.

Beyond clinical results, several articles explored how the life sciences industry is evolving. Topics included improving toxicity communication by moving beyond the term “manageable”, developing commercial strategies that integrate evidence generation from the outset, and recognising the growing role of GLP-1 therapies across multiple disease areas. Additional thought leadership emphasised the importance of high-quality localisation and culturally appropriate communication to improve participant understanding and engagement in global clinical trials.

Industry partnerships, investments and acquisitions

Strategic acquisitions remained a defining feature of the life sciences sector as organisations continued strengthening their pipelines through targeted investments.

GSK announced the acquisition of oncology specialist Nuvalent for $10.6 billion, expanding its portfolio of precision lung cancer therapies. Biogen agreed to acquire immunology-focused biotechnology company RayThera for up to $1 billion, while AbbVie announced a $10.9 billion acquisition of Apogee Therapeutics to strengthen its immunology and respiratory disease pipeline.

These transactions demonstrate continued investment in precision medicine, immunology and oncology, with companies seeking to accelerate innovation through strategic partnerships and acquisitions.

Healthcare initiatives and patient-centred innovation

Healthcare organisations continued to focus on policy, communication, inclusion and improving patient experience.

Thought leadership highlighted the importance of recognising obesity as a chronic disease within UK healthcare, alongside growing attention to men’s health, earlier intervention and reducing barriers to care. Broader discussions also explored Europe’s competitiveness in life sciences, emphasising the need for stronger policy alignment and investment to support innovation and patient access.

The European Medicines Agency marked Pride Month by reaffirming its commitment to diversity, inclusion and patient involvement within medicines regulation, while additional commentary examined how pharmaceutical companies can improve healthcare professional engagement through more integrated digital strategies.

Market access, patient engagement and healthcare communications

Healthcare communication, localisation and market access remained prominent themes throughout June.

Several articles examined how carefully chosen language can strengthen patient trust and engagement, while guidance on pharmaceutical exhibition design emphasised creating more welcoming, accessible experiences that encourage meaningful conversations rather than simply displaying information.

Market access discussions focused on how evolving trade agreements, pricing reforms and reimbursement policies are creating new opportunities to improve patient access to innovative medicines. At the same time, experts highlighted the importance of aligning commercial, regulatory and evidence-generation strategies to support successful product launches and long-term adoption.

Looking ahead

June’s developments demonstrate a life sciences industry increasingly balancing scientific innovation with patient-centred communication, healthcare accessibility and commercial strategy.

From breakthrough regulatory milestones and promising late-stage clinical data to major acquisitions, evolving healthcare policy and new approaches to patient engagement, organisations continue to invest across the full healthcare ecosystem to improve outcomes and expand access to innovation.

As regulators, healthcare providers, pharmaceutical companies and patient organisations continue to collaborate, success will increasingly depend not only on scientific advances but also on effective communication, evidence generation and delivering healthcare that is accessible, personalised and centred on patients’ real-world needs.

Essjay Solutions will continue to monitor these developments and provide insights into the latest regulatory, clinical, research, healthcare and market access trends.